JP2023522730A5 - - Google Patents
Info
- Publication number
- JP2023522730A5 JP2023522730A5 JP2022564073A JP2022564073A JP2023522730A5 JP 2023522730 A5 JP2023522730 A5 JP 2023522730A5 JP 2022564073 A JP2022564073 A JP 2022564073A JP 2022564073 A JP2022564073 A JP 2022564073A JP 2023522730 A5 JP2023522730 A5 JP 2023522730A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- variable region
- chain variable
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024218813A JP2025038088A (ja) | 2020-04-22 | 2024-12-13 | 抗ｃｄ７３／抗ｐｄ－１二重特異性抗体及びその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010324783.4 | 2020-04-22 | ||
| CN202010324783 | 2020-04-22 | ||
| CN202110270671 | 2021-03-12 | ||
| CN202110270671.X | 2021-03-12 | ||
| PCT/CN2021/089059 WO2021213475A1 (zh) | 2020-04-22 | 2021-04-22 | 抗cd73-抗pd-1双特异性抗体及其用途 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024218813A Division JP2025038088A (ja) | 2020-04-22 | 2024-12-13 | 抗ｃｄ７３／抗ｐｄ－１二重特異性抗体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023522730A JP2023522730A (ja) | 2023-05-31 |
| JP2023522730A5 true JP2023522730A5 (https=) | 2023-07-10 |
| JP7763780B2 JP7763780B2 (ja) | 2025-11-04 |
Family
ID=78094648
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022564073A Active JP7763780B2 (ja) | 2020-04-22 | 2021-04-22 | 抗ｃｄ７３／抗ｐｄ－１二重特異性抗体及びその使用 |
| JP2024218813A Pending JP2025038088A (ja) | 2020-04-22 | 2024-12-13 | 抗ｃｄ７３／抗ｐｄ－１二重特異性抗体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024218813A Pending JP2025038088A (ja) | 2020-04-22 | 2024-12-13 | 抗ｃｄ７３／抗ｐｄ－１二重特異性抗体及びその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230151111A1 (https=) |
| EP (1) | EP4141033A4 (https=) |
| JP (2) | JP7763780B2 (https=) |
| KR (1) | KR20230004726A (https=) |
| CN (1) | CN113527501B (https=) |
| AU (1) | AU2021261803B2 (https=) |
| BR (1) | BR112022021426A2 (https=) |
| CA (1) | CA3176321A1 (https=) |
| IL (1) | IL297432A (https=) |
| MX (1) | MX2022013311A (https=) |
| PH (1) | PH12022552785A1 (https=) |
| WO (1) | WO2021213475A1 (https=) |
| ZA (1) | ZA202211405B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022002028A2 (pt) * | 2019-08-02 | 2022-04-12 | Cttq Akeso Shanghai Biomed Tech Co Ltd | Anticorpo anti-pd-1 e uso farmacêutico do mesmo |
| CN120590533A (zh) * | 2020-10-23 | 2025-09-05 | 中山康方生物医药有限公司 | 抗cd73的抗体及其用途 |
| CN115073588B (zh) * | 2021-03-12 | 2024-06-18 | 中山康方生物医药有限公司 | 提高含有免疫球蛋白Fc片段的药物的安全性的方法 |
| JP2025512384A (ja) | 2022-04-13 | 2025-04-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｒｏｐ－２発現がんを治療するための併用療法 |
| KR20250026284A (ko) * | 2022-06-22 | 2025-02-25 | 아케소 바이오파마, 인크. | 약학 조성물 및 이의 용도 |
| CN116813786B (zh) * | 2023-08-03 | 2024-11-26 | 贝达药业股份有限公司 | 抗cd73抗体及其应用 |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| WO2011159877A2 (en) * | 2010-06-18 | 2011-12-22 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| GB2537445A (en) * | 2014-11-10 | 2016-10-19 | Medimmune Ltd | Binding molecules specific for CD73 and uses thereof |
| GB2538120A (en) | 2014-11-11 | 2016-11-09 | Medimmune Ltd | Therapeutic combinations comprising anti-CD73 antibodies and uses thereof |
| AU2015349878A1 (en) * | 2014-11-21 | 2017-05-25 | Bristol-Myers Squibb Company | Antibodies against CD73 and uses thereof |
| US20190330335A1 (en) * | 2015-10-06 | 2019-10-31 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| KR20250057128A (ko) * | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| EP3423494A1 (en) * | 2016-03-04 | 2019-01-09 | Bristol-Myers Squibb Company | Combination therapy with anti-cd73 antibodies |
| EP3494991A4 (en) * | 2016-08-05 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES |
| CN106967172B (zh) * | 2016-08-23 | 2019-01-08 | 康方药业有限公司 | 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途 |
| CN106977602B (zh) * | 2016-08-23 | 2018-09-25 | 中山康方生物医药有限公司 | 一种抗pd1单克隆抗体、其药物组合物及其用途 |
| KR20200096921A (ko) * | 2017-11-06 | 2020-08-14 | 코버스 파마슈티칼스, 인크. | 암 치료를 위한 아데노신 경로 억제제 |
| EP3762030A4 (en) * | 2018-03-09 | 2022-01-05 | Phanes Therapeutics, Inc. | ANTI-CD73 ANTIBODIES AND USES THEREOF |
| BR112020020826A2 (pt) * | 2018-04-12 | 2021-01-19 | Bristol-Myers Squibb Company | Terapia de combinação anticâncer com anticorpo antagonista de cd73 e anticorpo antagonista do eixo pd-1/pd-l1 |
| WO2020020307A1 (en) * | 2018-07-25 | 2020-01-30 | I-Mab Biopharma Co., Ltd. | Anti-cd73 anti-pd-l1 bispecific antibodies |
| CN109053895B (zh) * | 2018-08-30 | 2020-06-09 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途 |
| US20230159655A1 (en) * | 2020-04-22 | 2023-05-25 | Akeso Biopharma, Inc | Anti-cd73 antibody and use thereof |
-
2021
- 2021-04-22 CA CA3176321A patent/CA3176321A1/en active Pending
- 2021-04-22 KR KR1020227040580A patent/KR20230004726A/ko not_active Ceased
- 2021-04-22 IL IL297432A patent/IL297432A/en unknown
- 2021-04-22 EP EP21792313.5A patent/EP4141033A4/en active Pending
- 2021-04-22 BR BR112022021426A patent/BR112022021426A2/pt unknown
- 2021-04-22 CN CN202110440285.0A patent/CN113527501B/zh active Active
- 2021-04-22 AU AU2021261803A patent/AU2021261803B2/en active Active
- 2021-04-22 JP JP2022564073A patent/JP7763780B2/ja active Active
- 2021-04-22 WO PCT/CN2021/089059 patent/WO2021213475A1/zh not_active Ceased
- 2021-04-22 US US17/996,878 patent/US20230151111A1/en active Pending
- 2021-04-22 PH PH1/2022/552785A patent/PH12022552785A1/en unknown
- 2021-04-22 MX MX2022013311A patent/MX2022013311A/es unknown
-
2022
- 2022-10-18 ZA ZA2022/11405A patent/ZA202211405B/en unknown
-
2024
- 2024-12-13 JP JP2024218813A patent/JP2025038088A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023522730A5 (https=) | ||
| US11845795B2 (en) | NKp46 binding proteins | |
| US11202828B2 (en) | Therapeutic SIRP-α antibodies | |
| RU2767357C2 (ru) | Биспецифические антитела-ингибиторы контрольных точек | |
| EP3405492B1 (en) | Multispecific molecules targeting cll-1 | |
| JP2022542450A5 (https=) | ||
| AU2019356806B2 (en) | Antibody constructs binding 4-1BB and tumor-associated antigens and uses thereof | |
| CN115175702A (zh) | 用于体内生物靶向的材料和方法 | |
| CA2936785A1 (en) | Bi-specific cd3 and cd19 antigen-binding constructs | |
| CA2903056A1 (en) | Tetravalent bispecific antibodies | |
| US20230279108A1 (en) | Therapeutic sirp-alpha antibodies | |
| CN115175938A (zh) | 制导和导航控制(gnc)抗体样蛋白及其制备和使用方法 | |
| US20250270315A1 (en) | Novel anti-sirpa antibodies | |
| JP2024540148A5 (https=) | ||
| AU2022332499A1 (en) | Fap/cd40 binding molecule and medicinal use thereof | |
| JP2024515396A5 (https=) | ||
| CA3255392A1 (en) | Anti-Dectin-1 Antibodies and Their Methods of Use | |
| AU2021224787A1 (en) | CD137 binding molecules and uses thereof | |
| WO2018237364A1 (en) | Asymmetric heterodimeric fc-scfv fusion anti-globo h and anti-cd3 bispecifc antibody and uses thereof in caner therapy | |
| US20230265202A1 (en) | Antibody constructs binding 4-1bb and folate receptor alpha and uses thereof | |
| RU2024107310A (ru) | Радиоконъюгаты к psma и способы их применения | |
| HK40073540A (zh) | 制导和导航控制(gnc)抗体样蛋白及其制备和使用方法 |